Osaka, Japan

Akiharu Ishida

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Akiharu Ishida: Innovator in Somatostatin Receptor Agonists

Introduction

Akiharu Ishida is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medical research, particularly in the development of compounds that target somatostatin receptors. With a total of 4 patents to his name, Ishida's work is paving the way for new therapeutic options.

Latest Patents

One of Ishida's latest patents focuses on a compound that exhibits agonistic activity on somatostatin receptors. This compound is designed for medical purposes, specifically as an orally-available and low-toxic somatostatin receptor subtype 2 agonist. The compound, represented by a specific general formula, is a non-peptidic low-molecular compound that demonstrates strong agonist activity. Its low toxicity makes it particularly useful for preventing and treating somatostatin-related diseases, such as acromegaly and gastrointestinal obstruction.

Career Highlights

Ishida is currently employed at Ono Pharmaceutical Co., Ltd., where he continues to innovate in the field of pharmacology. His research has the potential to significantly impact the treatment of various medical conditions related to somatostatin receptors.

Collaborations

Throughout his career, Ishida has collaborated with notable colleagues, including Takeshi Matsushita and Tetsuya Sekiguchi. These collaborations have further enhanced his research and development efforts.

Conclusion

Akiharu Ishida's contributions to the field of somatostatin receptor agonists highlight his role as a key innovator in medical research. His work not only advances scientific understanding but also offers hope for effective treatments for serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…